Seer, Inc. ((SEER)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Seer’s latest earnings call mixed sobering near-term numbers with a confident long-term narrative, as management acknowledged a steep revenue and margin pullback while leaning hard on growing scientific validation, new biobank partnerships and tighter cost control. The tone was cautious but constructive, with leadership signaling patience, discipline and a belief that today’s pressure could set up tomorrow’s upside.
Rapid Expansion of Scientific Validation
Publications validating Seer’s Proteograph technology climbed to 84, up from 42 as of March 2025 and just 3 in 2022, effectively doubling year over year. This rapid growth in peer-reviewed data is strengthening the platform’s credibility with researchers and biopharma, a key asset as competition intensifies.
Population-Scale Biobank Deals Build Long-Term Demand
Seer highlighted a new PRECISE-SG100K collaboration with PRECISE and Thermo Fisher that will generate proteomic data for 10,000 participants, with potential expansion to 100,000. Combined with ongoing work at Korea University and in an NIH-funded multi-omic study, these population-scale projects could become powerful demand engines over time.
Clinical Signal in Early Cancer Detection
Customer PrognomIQ used Proteograph in its ProVue Lung study, where among the first 78 high-risk adults the test detected 8 lung cancers with 89% overall sensitivity at 64% specificity. Importantly, stage 1 sensitivity was 83%, underscoring Proteograph’s potential to support early cancer detection in real-world translational settings.
Upgraded Commercial Leadership for the Next Phase
The company appointed Tony Bazarko as Chief Commercial Officer, a move aimed at scaling its go-to-market execution at a pivotal point in Seer’s evolution. Management expects the new leadership to accelerate adoption in biobanks and biopharma, and to better convert growing scientific validation into commercial traction.
IP Fortress: Wins, Portfolio Depth and Litigation
Seer reported that the patent board upheld 23 of 29 claims in a nanoparticle enrichment patent, supporting the strength of its core IP. With more than 250 patents and applications, 84 already issued, the company has also filed a patent infringement suit against a competitor, signaling a willingness to defend its technology aggressively.
Product and Analytics Pipeline Stays Busy
On the innovation front, Seer rolled out the SP200 system and Proteograph One Assay to support large-scale studies and is advancing a next-generation detector, with data expected later this year. It also updated its POS software with chatbot and notebook interfaces and released a Raviant DIA preprint, pointing to sustained investment in both hardware and informatics.
Operating Costs Pulled Back Without Halting Investment
Total operating expenses dropped to $18.2 million in Q1 2026 from $22.8 million a year earlier, a roughly 20% year-over-year reduction. Management framed the cut as deliberate discipline rather than retrenchment, saying it is reallocating spend toward the highest-priority growth and product initiatives.
Losses Narrow as Cash Cushion Remains Large
Net loss improved to $16.8 million from $19.9 million in the prior-year quarter, a reduction of about 15.6%. Seer ended Q1 with $219.5 million in cash, equivalents and investments and believes this balance is sufficient to carry the company to cash-flow breakeven, even as it continues to invest.
Aggressive Share Repurchases Signal Confidence
Seer repurchased roughly 1.5 million Class A shares in the quarter at an average price of $1.78. In total, the company has bought back about 13.2 million shares under its current program at a volume-weighted average price of $1.86, using about $24.5 million and shrinking its common share count by roughly 15%.
Revenue Slide Highlights Near-Term Commercial Strain
Q1 2026 revenue fell to $2.8 million from $4.2 million a year ago, a steep 33% year-over-year decline that underscored near-term commercial headwinds. Management cited depressed academic funding, heavier competition from lower-priced imitators and timing issues tied to its commercial transition.
Margin Compression and Mix Challenges
Gross profit was about $1.0 million, translating to a 35% gross margin versus 49% in Q1 2025, as lower volume weakened fixed-cost absorption. Executives stressed that quarter-to-quarter margin will remain sensitive to the mix of instruments, consumables and services, but reiterated a long-term target band of 70% to 75% once scale improves.
Service Revenue Volatility Adds to Uncertainty
Service revenue came in at $0.6 million, including $0.1 million from related parties, and was down against prior periods. The company pointed to the inherent lumpiness of its STAC projects and the absence of a large service engagement in Q1, signaling that service pull-through may be uneven in the near term.
Free Cash Flow Still Negative as Build-Out Continues
Free cash flow was about negative $15.7 million in the quarter, driven by roughly $15.4 million of operating cash burn and about $0.27 million in capex. While this underscores that Seer is still consuming cash, management argued that the current balance sheet provides sufficient runway to bridge to breakeven.
Competitive Imitators and Legal Costs Weigh on the Model
Leadership flagged increased activity from lower-priced, lower-quality imitator products that are pressuring customer budgets and muddying market education. In response, Seer is pursuing litigation to protect its IP, but these efforts are expected to sustain higher legal and professional expenses at least through the next quarter.
Revenue Mix and Scale Key to Margin Recovery
Management emphasized that margins will fluctuate depending on the balance of instrument, consumable and service revenue in any given quarter. Achieving the long-term 70% to 75% margin goal will require greater scale and a richer consumables mix, something the company expects to build gradually as installed instruments ramp.
Guidance and Outlook: Cautious Growth, Long Runway
Seer reaffirmed its 2026 revenue outlook of $16.0 million to $18.0 million, implying about 3% growth at the midpoint versus 2025 despite a weak start to the year. Management expects utilization and consumable pull-through to strengthen primarily in the back half, while acknowledging that NIH funding pressures and imitator competition will keep near-term expectations conservative.
Seer’s earnings call painted a picture of a company in transition, wrestling with short-term revenue, margin and cash-flow headwinds while building what it argues is a defensible and increasingly validated proteomics franchise. For investors, the story now hinges on whether rising scientific and biobank traction can translate into steady commercial scale before the cash cushion thins.